vs
Side-by-side financial comparison of Citi Trends Inc (CTRN) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $197.1M, roughly 1.7× Citi Trends Inc). HAEMONETICS CORP runs the higher net margin — 13.2% vs -3.5%, a 16.7% gap on every dollar of revenue. On growth, Citi Trends Inc posted the faster year-over-year revenue change (10.1% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $767.0K). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -4.3%).
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CTRN vs HAE — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $197.1M | $339.0M |
| Net Profit | $-6.9M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | -3.7% | 19.9% |
| Net Margin | -3.5% | 13.2% |
| Revenue YoY | 10.1% | -2.7% |
| Net Profit YoY | 3.6% | 19.3% |
| EPS (diluted) | $-0.86 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.1M | $339.0M | ||
| Q3 25 | $190.8M | $327.3M | ||
| Q2 25 | $201.7M | $321.4M | ||
| Q1 25 | $211.2M | $330.6M | ||
| Q4 24 | $179.1M | $348.5M | ||
| Q3 24 | $176.6M | $345.5M | ||
| Q2 24 | $186.3M | $336.2M | ||
| Q1 24 | $215.2M | — |
| Q4 25 | $-6.9M | $44.7M | ||
| Q3 25 | $3.8M | $38.7M | ||
| Q2 25 | $871.0K | $34.0M | ||
| Q1 25 | $-14.2M | $58.0M | ||
| Q4 24 | $-7.2M | $37.5M | ||
| Q3 24 | $-18.4M | $33.8M | ||
| Q2 24 | $-3.4M | $38.4M | ||
| Q1 24 | $3.6M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | — |
| Q4 25 | -3.7% | 19.9% | ||
| Q3 25 | 1.8% | 17.9% | ||
| Q2 25 | 0.2% | 16.8% | ||
| Q1 25 | 0.6% | 21.6% | ||
| Q4 24 | -4.9% | 16.9% | ||
| Q3 24 | -14.1% | 15.0% | ||
| Q2 24 | -3.7% | 11.8% | ||
| Q1 24 | 1.8% | — |
| Q4 25 | -3.5% | 13.2% | ||
| Q3 25 | 2.0% | 11.8% | ||
| Q2 25 | 0.4% | 10.6% | ||
| Q1 25 | -6.7% | 17.5% | ||
| Q4 24 | -4.0% | 10.8% | ||
| Q3 24 | -10.4% | 9.8% | ||
| Q2 24 | -1.8% | 11.4% | ||
| Q1 24 | 1.7% | — |
| Q4 25 | $-0.86 | $0.95 | ||
| Q3 25 | $0.46 | $0.81 | ||
| Q2 25 | $0.11 | $0.70 | ||
| Q1 25 | $-1.70 | $1.17 | ||
| Q4 24 | $-0.86 | $0.74 | ||
| Q3 24 | $-2.21 | $0.66 | ||
| Q2 24 | $-0.42 | $0.74 | ||
| Q1 24 | $0.43 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $107.8M | $911.5M |
| Total Assets | $464.3M | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M | ||
| Q1 24 | — | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $107.8M | $911.5M | ||
| Q3 25 | $113.2M | $849.2M | ||
| Q2 25 | $108.6M | $882.3M | ||
| Q1 25 | $113.2M | $820.8M | ||
| Q4 24 | $130.3M | $906.9M | ||
| Q3 24 | $136.6M | $878.9M | ||
| Q2 24 | $154.8M | $905.4M | ||
| Q1 24 | $157.7M | — |
| Q4 25 | $464.3M | $2.5B | ||
| Q3 25 | $457.4M | $2.4B | ||
| Q2 25 | $437.4M | $2.5B | ||
| Q1 25 | $462.8M | $2.5B | ||
| Q4 24 | $467.1M | $2.5B | ||
| Q3 24 | $506.7M | $2.5B | ||
| Q2 24 | $484.1M | $2.5B | ||
| Q1 24 | $518.7M | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.6M | $93.6M |
| Free Cash FlowOCF − Capex | $767.0K | $87.2M |
| FCF MarginFCF / Revenue | 0.4% | 25.7% |
| Capex IntensityCapex / Revenue | 4.0% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $11.9M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | $93.6M | ||
| Q3 25 | $3.9M | $111.3M | ||
| Q2 25 | $-11.0M | $17.4M | ||
| Q1 25 | $28.5M | $116.6M | ||
| Q4 24 | $-18.4M | $43.8M | ||
| Q3 24 | $5.6M | $48.8M | ||
| Q2 24 | $-19.6M | $-27.4M | ||
| Q1 24 | $23.3M | — |
| Q4 25 | $767.0K | $87.2M | ||
| Q3 25 | $-1.7M | $106.3M | ||
| Q2 25 | $-13.1M | $13.6M | ||
| Q1 25 | $26.0M | $100.9M | ||
| Q4 24 | $-20.4M | $35.2M | ||
| Q3 24 | $1.7M | $39.4M | ||
| Q2 24 | $-21.2M | $-33.1M | ||
| Q1 24 | $20.0M | — |
| Q4 25 | 0.4% | 25.7% | ||
| Q3 25 | -0.9% | 32.5% | ||
| Q2 25 | -6.5% | 4.2% | ||
| Q1 25 | 12.3% | 30.5% | ||
| Q4 24 | -11.4% | 10.1% | ||
| Q3 24 | 0.9% | 11.4% | ||
| Q2 24 | -11.4% | -9.8% | ||
| Q1 24 | 9.3% | — |
| Q4 25 | 4.0% | 1.9% | ||
| Q3 25 | 2.9% | 1.5% | ||
| Q2 25 | 1.0% | 1.2% | ||
| Q1 25 | 1.2% | 4.7% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 2.2% | 2.7% | ||
| Q2 24 | 0.9% | 1.7% | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | 1.01× | 2.88× | ||
| Q2 25 | -12.59× | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | 6.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRN
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
